Source: State of Affairs

LaborDr.Merk: Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Boehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk &... Read More The post Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program first appeared on State of Affairs .

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Ingrid Rapp's photo - CEO of LaborDr.Merk

CEO

Ingrid Rapp

CEO Approval Rating

90/100

Read more